← All sarcoma trials
Recruiting nowPhase 2Ages 14 Years to 70 Years

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Sponsor: Peking University People's Hospital · NCT06714383 on ClinicalTrials.gov ↗

Conditions studied

Osteosarcoma

What it tests

  • Trilaciclibdrug
  • Pirarubicindrug
  • Lobaplatindrug

Where it's running1 site

1 international site
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Written informed consent signed;
2. Classic osteosarcoma confirmed by histopathology (high grade);
3. Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria;
4. Planned to receive neoadjuvant chemotherapy;
5. Measurable disease on CT by RECIST 1.1.
6. No antitumor system therapy received;
7. ECOG 0-1
8. Adequate organ function.
9. Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.

Exclusion Criteria:

1. History of malignancies of other type;
2. Allergic to study agent;
3. History of psychotropic substance abuse, alcohol or drug use;
4. The researchers considered inappropriate to join the study of any cause.

Updated 2024-12-03 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.